GTBP (STOCKS)
GT Biopharma Inc. Common Stock
$0.380100
+0.011100 (+3.01%)
Prev close: $0.369000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Michael Breen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $11.97M
- Employees
- 1
- P/E (TTM)
- -0.03
- P/B (TTM)
- 1.63
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-4.84 | $-0.22 | -4.6156 | -2,056.86% |
|
Sep 2025 (Q3)
|
$-0.79 | $-0.39 | -0.4024 | -103.82% |
|
Jun 2025 (Q2)
|
$-0.52 | $-0.69 | +0.1736 | +25.03% |
|
Mar 2025 (Q1)
|
$-0.33 | $-0.65 | +0.3228 | +49.45% |
Financial Statements
| Nonoperating Income/Loss | -$15.93M |
| Selling, General, and Administrative Expenses | $8.95M |
| Research and Development | $3.47M |
| Operating Income/Loss | -$12.42M |
| Income/Loss From Continuing Operations After Tax | -$28.35M |
| Income/Loss From Continuing Operations Before Tax | -$28.35M |
| Net Income/Loss | -$28.35M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$28.35M |
| Net Income/Loss Available To Common Stockholders, Basic | -$34.45M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $6.10M |
| Preferred Stock Dividends And Other Adjustments | $6.10M |
| Basic Earnings Per Share | -$6.68 |
| Diluted Earnings Per Share | -$6.68 |
| Basic Average Shares | 5,513,255 |
| Diluted Average Shares | 5,513,255 |
| Assets | $8.11M |
| Current Assets | $8.11M |
| Noncurrent Assets | $0.00 |
| Liabilities | $2.32M |
| Current Liabilities | $2.32M |
| Accounts Payable | $748.00K |
| Other Current Liabilities | $1.57M |
| Noncurrent Liabilities | $0.00 |
| Equity | $5.79M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $5.79M |
| Liabilities And Equity | $8.11M |
| Net Cash Flow From Operating Activities | -$12.91M |
| Net Cash Flow From Operating Activities, Continuing | -$12.91M |
| Net Cash Flow From Investing Activities | -$2.86M |
| Net Cash Flow From Investing Activities, Continuing | -$2.86M |
| Net Cash Flow From Financing Activities | $15.78M |
| Net Cash Flow From Financing Activities, Continuing | $15.78M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$28.35M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$28.35M |
| Other Comprehensive Income/Loss | $0.00 |